ATRA
Atara Biotherapeutics Inc
8.90$
-4.8%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 99.9% | 99.9% | 98.7% | 79.1% | 82.0% | 79.6% | 89.0% | 82.2% | 78.4% | 61.6% | 59.5% | 60.4% | |
| 20.6% | 7.3% | 18.2% | 36.4% | 15.5% | 21.7% | 34.1% | 22.7% | 24.7% | 15.6% | 22.9% | 41.9% | |
| 98.1% | 98.6% | 96.9% | 76.3% | 79.0% | 75.6% | 85.1% | 79.3% | 64.5% | 31.3% | 39.0% | 41.9% | |
| – | – | – | – | – | – | 0.2% | 0.2% | 10.7% | 20.6% | 1.4% | 6.2% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | 0.0% | 0.4% | 5.9% | 9.8% | 0.0% | |
| 0.0% | 0.1% | 1.2% | 20.3% | 17.5% | 15.8% | 8.6% | 17.1% | 1.7% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 2.8% | 3.0% | 3.9% | 18.3% | 13.5% | 15.2% | 21.4% | 40.3% | 66.4% | 160.0% | 189.2% | 290.3% | |
| 2.6% | 3.0% | 3.7% | 12.7% | 10.2% | 10.7% | 14.1% | 22.6% | 21.0% | 85.9% | 123.4% | 73.7% | |
| – | – | – | 0.2% | 0.1% | 0.5% | 0.3% | 0.6% | 3.6% | 7.4% | 12.8% | 53.3% | |
| 0.4% | 0.4% | 1.1% | 6.8% | 0.9% | 2.3% | 1.2% | 3.7% | 1.8% | 2.2% | 4.0% | 0.6% | |
| 0.0% | 0.0% | 0.0% | 4.8% | – | – | – | – | – | – | – | – | |
| 97.2% | 97.0% | 96.1% | 81.7% | 86.5% | 84.8% | 78.6% | 59.7% | 33.6% | -60.0% | -89.2% | -190.3% | |
| -38.5% | -30.2% | -67.1% | -136.2% | -134.6% | -238.5% | -191.2% | -312.9% | -449.8% | -1,189.8% | -1,883.2% | -9,991.9% | |
| 0.2% | 0.3% | 0.4% | 0.5% | 0.4% | 0.6% | 0.5% | 0.8% | 1.1% | 2.6% | 6.9% | 62.9% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.